Louis A. Cannon is Director at Corindus Vascular Robotics, Inc. (CVRS). They have made 10 open-market trades across 1 company since 2017, most recently 2019-10-29.
CIK 0001700257
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $1.8M since 2017, never a sale. Across 10 scored buys the stock is up 41.5% at ninety days, and 40.7 points ahead of the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| CVRS | 303,440 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2019-10-09 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 70% | 100% |
| Avg Move | +11.6% | +20.0% | +41.5% |
| Alpha | +10.8% | +17.8% | +40.7% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CVRS | BUY | 2019-05-22 | 2019-05-23 | $2.63 | $20K | +1.2% | +26.9% | +68.8% |
| CVRS | BUY | 2019-03-27 | 2019-03-27 | $1.80 | $18K | +20.1% | +11.7% | +70.9% |
| CVRS | BUY | 2019-03-12 | 2019-03-13 | $1.38 | $1.6M | +16.8% | +30.4% | +77.0% |
| CVRS | BUY | 2018-08-23 | 2018-08-27 | $1.03 | $31K | +5.8% | +31.1% | +20.4% |
| CVRS | BUY | 2018-08-21 | 2018-08-23 | $0.99 | $30K | +1.0% | +35.6% | +20.8% |
| CVRS | BUY | 2018-08-10 | 2018-08-14 | $0.96 | $30K | +13.2% | +33.0% | +39.6% |
| CVRS | BUY | 2018-05-24 | 2018-05-25 | $0.79 | $13K | -6.4% | -5.7% | +31.6% |
| CVRS | BUY | 2018-05-16 | 2018-05-18 | $0.81 | $5K | -11.8% | -14.1% | +7.6% |
| CVRS | BUY | 2017-11-10 | 2017-11-14 | $0.81 | $19K | +72.5% | +53.6% | +39.1% |
| CVRS | BUY | 2017-03-21 | 2017-03-23 | $1.30 | $35K | +3.3% | -2.4% | +39.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.